BCBP vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BCBP exhibits weak financial health with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. The stock trades at a significant premium to its Graham Number of $4.79, currently priced at $7.86, despite deteriorating fundamentals including negative earnings and revenue growth. Profitability metrics like ROE (0.86%) and ROA (0.08%) are extremely weak, while the dividend is unsustainable with a payout ratio exceeding 1000%. Although analysts recommend a 'buy' with a $9.50 target, the company's track record of earnings misses and declining performance raises serious concerns.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BCBP vs BRK-B: Head-to-Head Comparison
This page compares BCB Bancorp, Inc. (BCBP) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.